Morphogene Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 17-12-2024
- Paid Up Capital ₹ 1.33 Cr
as on 17-12-2024
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -80.12%
(FY 2020)
- Profit -89.81%
(FY 2020)
- Ebitda -89.21%
(FY 2020)
- Net Worth -4.74%
(FY 2020)
- Total Assets 0.48%
(FY 2020)
About Morphogene Biotech
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.33 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rajshree Mohta, Sanjay Periwal, and Karan Kakkad serve as directors at the Company.
- CIN/LLPIN
U24233MP2013PTC030485
- Company No.
030485
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Apr 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Morphogene Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karan Kakkad  | Director | 26-Apr-2018 | Current |
| Rajshree Mohta | Director | 09-Apr-2013 | Current |
| Sanjay Periwal | Director | 26-Aug-2013 | Current |
Financial Performance and Corporate Structure Insights of Morphogene Biotech.
Morphogene Biotech Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 80.12% decrease. The company also saw a substantial fall in profitability, with a 89.81% decrease in profit. The company's net worth dipped by a decrease of 4.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Morphogene Biotech?
In 2020, Morphogene Biotech had a promoter holding of 2.26% and a public holding of 97.74%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pretty Dealtrade Private LimitedActive 14 years 8 monthsRajshree Mohta and Karan Kakkad are mutual person
- Primerose Dealtrade Private LimitedActive 14 years 7 months
Rajshree Mohta and Karan Kakkad are mutual person
- Mahurat Commotrade Private LimitedActive 14 years 10 months
Rajshree Mohta and Karan Kakkad are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Morphogene Biotech?
Unlock and access historical data on people associated with Morphogene Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Morphogene Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Morphogene Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
